Mohammad Barzegar-Jalali
Overview
Explore the profile of Mohammad Barzegar-Jalali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heydari S, Barzegar-Jalali M, Heydari M, Radmehr A, Paiva-Santos A, Kouhsoltani M, et al.
Bioimpacts
. 2024 Nov;
14(6):30243.
PMID: 39493898
Introduction: Follicular delivery is one of the targeted drug delivery methods aiming to target the hair follicles. The accumulation and retention time of targeted drugs is enhanced when nanoparticles are...
2.
Barzegar-Jalali M, Sheikhi-Sovari A, Martinez F, Seyfinejad B, Rahimpour E, Jouyban A
BMC Chem
. 2024 Sep;
18(1):178.
PMID: 39300475
This study investigates the solubility behavior of Naproxen (NAP) in binary solvent mixtures of 1-propanol (1-PrOH) and 2-propanol (2-PrOH) with ethylene glycol (EG) across a range of temperatures. The solubility...
3.
Khaleseh F, Barzegar-Jalali M, Zakeri-Milani P, Karami Z, Saghatchi Zanjani M, Valizadeh H
Iran J Basic Med Sci
. 2024 May;
27(7):857-867.
PMID: 38800017
Objectives: Lipid-based drug delivery systems (DDS) can improve the pharmacokinetic (PK) parameters of some drugs. Especially those with a high volume of distribution (Vd) leading to off-target accumulation and toxicity....
4.
Armani E, Jafari P, Hemmati S, Rahimpour E, Barzegar-Jalali M, Jouyban A
BMC Chem
. 2023 Nov;
17(1):171.
PMID: 38017539
Mesalazine (5-ASA) is a medication utilized to treat inflammatory bowel diseases involving ulcerative colitis and Crohn's disease. Mesalazine has fewer side effects but the low solubility and bioavailability of it...
5.
Mehdizadeh F, Mohammadzadeh R, Nazemiyeh H, Mesgari-Abbasi M, Barzegar-Jalali M, Eskandani M, et al.
Adv Pharm Bull
. 2023 Jun;
13(2):283-289.
PMID: 37342366
(L.) Moench is a member of the family and is traditionally used mainly due to its immunostimulatory properties. Various compounds including alkylamides and chicoric acid were reported as active ingredients...
6.
Memar M, Rezaee M, Barzegar-Jalali M, Gholikhani T, Adibkia K
Curr Microbiol
. 2023 Apr;
80(5):173.
PMID: 37029840
The present study aimed to investigate the biocompatibility, antibacterial/anti-biofilm effects of ciprofloxacin-loaded calcium carbonate (Cip- loaded CaCO) nanoparticles against the common organisms responsible for osteomyelitis. The antibacterial and biofilm inhibitory...
7.
Molavi F, Barzegar-Jalali M, Hamishehkar H
Bioimpacts
. 2023 Jan;
12(6):501-513.
PMID: 36644544
Glatiramer acetate (GA) is a newly emerged therapeutic peptide to reduce the frequency of relapses in multiple sclerosis (MS). Despite its good performance in controlling MS, it is not widely...
8.
Gholikhani T, Kumar S, Valizadeh H, Mahdinloo S, Adibkia K, Zakeri-Milani P, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430951
Aptamers are synthetic single-stranded oligonucleotides (such as RNA and DNA) evolved in vitro using Systematic Evolution of Ligands through Exponential enrichment (SELEX) techniques. Aptamers are evolved to have high affinity...
9.
Dolatkhah M, Hashemzadeh N, Barar J, Adibkia K, Aghanejad A, Barzegar-Jalali M, et al.
Nanomedicine (Lond)
. 2021 Sep;
16(24):2155-2174.
PMID: 34565179
Nanocomposites of graphene oxide (GO) loaded with PEGylated superparamagnetic iron oxide nanoparticles and grafted with methotrexate and stimuli-responsive linkers (GO-SPION-MTX) were developed for photothermal and chemotherapy of breast cancer. PEGylated...
10.
Hashemzadeh N, Dolatkhah M, Aghanejad A, Barzegar-Jalali M, Omidi Y, Adibkia K, et al.
Nanomedicine (Lond)
. 2021 Sep;
16(24):2137-2154.
PMID: 34530630
The efficiency of mesoporous silica magnetic nanoparticles (MSMNP) as a targeted drug-delivery system was investigated. The superparamagnetic iron oxide nanoparticles (NP) were synthesized, coated with mesoporous silica and conjugated with...